Copenhagen, 2013-03-12 17:48 CET (GLOBE NEWSWIRE) --
The annual general meeting of ALK held on 12 March 2013 transacted the following business:
- Adoption of the annual report 2012 and discharge of the Board of Directors and Board of Management.
- Declaration of an ordinary dividend of DKK 5.00 per A/B share of DKK 10.
- Approval of the remuneration to the Board of Directors for the present year. The remuneration remains unchanged compared with 2012.
- For the period up to the next annual general meeting, the Board of Directors was authorised to let the company acquire own B shares with a nominal value of up to 10% of the share capital at the market price for B shares on the date of acquisition, subject to a deviation of up to 10%.
- For the period up to and including the day of the annual general meeting to be held in 2014, the Board of Directors was authorised to increase the company's share capital by issue of new shares with a nominal value of up to DKK 10,128,360, equivalent to A shares with a nominal value of up to DKK 920,760 and B shares with a nominal value of up to DKK 9,207,600.
- Steen Riisgaard, Christian Dyvig, Thorleif Krarup, Anders Gersel Pedersen and Jes Østergaard were re-elected to the Board of Directors. Jakob Riis, Executive Vice President of Marketing & Medical Affairs at Novo Nordisk, was elected as a new member of the Board of Directors.
- DELOITTE Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor.
Following the annual general meeting, the Board of Directors held its first meeting. Steen Riisgaard was re-elected Chairman and Christian Dyvig was re-elected Vice Chairman of the Board of Directors.
ALK-Abelló A/S
Steen Riisgaard
Chairman
For further information please contact:
Jens Bager, President and CEO, tel.+45 4574 7576